India
2010
2010: India’s intervention to the WTO TRIPS Council: TRIPS plus enforcement trends, 2010-06-10
2011
2011: Karl De Gucht writes Andris Piebalgs on topic of European Union IPR demands on India and other developing countries, 2011-05-28
2011: WTO TRIPS Council: India questions the United States on eBay v. MercExchange precedent as alternative to Paragraph 6 mechanism, 2011-10-26
2012
2012: KEI Statement on India’s granting of compulsory license to patents on cancer drug sorafenib (NATCO Vs. BAYER), 2012-03-12
2012: Nexavar compulsory license case in India, 2012-06-29
2012: USPTO and Congress bash India over the Nexavar compulsory license, 2012-06-30
2012: USPTO “clarifies” June 27, 2012 testimony on biologics exclusivity and India compulsory license, 2012-07-04
2012: September 2011: Spotlight on India at the WTO Trade Policy Review, 2012-08-28
2012: WTO TRIPS Council (November 2012): Intervention of India on Intellectual Property and Innovation, 2012-11-08
2013
2013: India Intellectual Property Appeals Board (IPAB) upholds compulsory license on cancer drug in Bayer v Natco, 2013-03-04
2013: WTO TRIPS Council-Intervention of India on Intellectual Property and Innovation: Small and medium Sized Enterprises, 2013-03-05
2013: India pressured by U.S. Congressional committee, Pfizer, over drug patents, 2013-03-26
2013: More notes on the India EU FTA (BTIA), 2013-03-28
2013: KEI comments to House Trade Subcommittee on U.S.-India Trade Relations, 2013-03-28
2013: WTO TRIPS Council: Intervention of India on Intellectual Property, Climate Change and Development (June 2013), 2013-06-12
2013: 170 Members of Congress Send Letter to Obama Criticizing India on Intellectual Property, 2013-06-20
2014
2014:Bayer CEO Marijn Dekkers explains: Nexavar cancer drug is for “western patients who can afford it. 2014-01-23
2014: Transcript of Bayer CEO Marjin Dekkers quote at the December 3, 2013 FT Event, regarding India compulsory license of Nexavar, 2014-02-07
2014: Alliance for Fair Trade with India (AFTI): Ground zero for trade sanctions against India, 2014-02-10
2014: BIO discussion of India, 2014-02-10
2014: IPO discussion of India, 2014-02-10
2014: NAM discussion of India, 2014-02-10
2014: NFTC discussion of India, 2014-02-10
2014: PhRMA discussion of India, 2014-02-10
2014: U.S. Chamber of Commerce (Global Intellectual Property Center) discussion of India, 2014-02-10
2014: Public Comments by Brian Pomper-Executive Director of the Innovation Alliance and Alliance for Fair Trade with India, 2014-02-12
2014: WTO TRIPS Council (February 2014) – India’s intervention on Non-Violation and Situation Complaints, 2014-02-26
2014: Rajasingh on India-US dispute over patents on dasatinib, a drug to treat leukemia, 2014-10-24
2014: Comments to USTR on the Out-of-Cycle Review for India due October 31, 2014. 2014-10-24
2015
2015: WTO Trade Policy Review of the United States: USTR deflects questions from India on compulsory licensing (December 2014), 2015-02-21
2015: WTO Trade Policy Review of India- EU, Japan, Switzerland and the US question India over Section 3(d) and Compulsory Licensing, 2015-08-03
2015: 17 WTO Members (Brazil, China, India, Russia) submit draft Ministerial Decision on Non-Violation and Situation Complaints, 2015-08-12
2016
2016: Industry USTR filings refer to Indian Government agreement to block compulsory licenses, 2016-03-01
2016: 9 November 2016 – WTO TRIPS Council – India’s intervention on the Report of the UN High-Level Panel on Access to Medicines, 2016-11-10
2016: 8 November 2016 – TRIPS Council – India’s intervention on the Paragraph 6 Mechanism, 2016-11-14
2017
2017: 1 March 2017 – WTO TRIPS Council – India’s intervention on the Report of the UN High-Level Panel on Access to Medicines, 2017-03-03
2017: WTO TRIPS Council: Brazil, China, Fiji, India, and South Africa table agenda item on IP and the Public Interest, 2017-06-06
2017: WTO TRIPS Council – Statement of India on IP and the Public Interest – Compulsory Licensing, 2017-06-14
2017: WTO TRIPS Council (October 2017):India asks EU, Malaysia to share details of their respective compulsory licenses, 2017-10-24
Indonesia
2017
2017: Asia Pacific Group asks WIPO to initiate exploratory discussions on the Report of the UN High Level Panel on Access to Medicines, 2017-12-11
Malaysia
2017
2017: WTO TRIPS Council (October 2017): South Africa highlights examples of compulsory licensing in Germany, Malaysia, and the US, 2017-10-21
2017: WTO TRIPS Council (October 2017): India asks EU, Malaysia to share details of their respective compulsory licenses, 2017-10-24
Thailand
2007
2007: Geneva Q&A Session on Thai White Paper. 2007-03-08
2007: Notes from March 16th 2007 U.S. Capitol Briefing on Thailand’s Compulsory Licenses, 2007-03-16
2007: KEI Statement on USTR 301 list reference to Thailand, 2007-04-30
2007: Thailand’s Compulsory Licensing Controversy, 2007-06-20
2008
2008: KEI Letter to Thailand Prime Minister and Health Minister, regarding compulsory licensing decisions, 2008-08-05
2009
2009: PhRMA Special 301 submission on Thailand, 2009-03-13
2010
2010: FOIA document: In 2007, US Ambassador Ralph Boyce was pleased that Abbott withdrew life saving drugs from market in Thailand, 2010-03-07
2012
2012: US department of Commerce heavily redacts FOIA request regarding Thailand compulsory license, 2012-10-05
2013
2013: Four Department of State cables on Thailand, for Special 301 Review (Years 2009 to 2011), 2013-06-12